Hatch-Waxman Integrity Act of 2018
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Dec 11, 2018)
Hatch-Waxman Integrity Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.
What just happenedDec 11, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who’s behind it
- Introduced in HouseDec 11, 2018
- Dec 11, 2018IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Financial Services Committee - Dec 11, 2018IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Dec 11, 2018IntroReferralIntro-H
Introduced in House
- Dec 11, 2018IntroReferral1000
Introduced in House